0001058290-26-000031
SEC filingQ2 营收增4.5%至$5,481M,但净利降1.4%,受Project Leap重组费用拖累。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $5,481M | $5,245M | +4.5% |
| Gross Profit | $1,829M | $1,766M | +3.6% |
| Gross Margin | 33.4% | 33.7% | -30 bps |
| Operating Income | $874M | $817M | +7.0% |
| Operating Margin | 15.9% | 15.6% | +30 bps |
| Net Income | $636M | $645M | -1.4% |
| Diluted EPS | $1.36 | $1.31 | +3.8% |
| Adjusted Operating Margin | 16.0% | 15.6% | +40 bps |
| Adjusted Diluted EPS | $1.37 | $1.31 | +4.6% |
| Operating Cash Flow | $832M (H1) | $798M (H1) | +4.3% |
| Free Cash Flow | $657M (H1) | $654M (H1) | +0.5% |
增长桥:Q2营收增长$236M(+4.5%),恒定汇率+4.1%。主要驱动:近期赢得的大型交易逐步放量、Intuitive Operations and Automation及AI/analytics服务需求增长、第三方产品销售收入贡献170 bps、近期收购贡献约100 bps。分地区看,North America增长5.5%,Europe增长2.5%(恒定汇率0.8%),Rest of World下降1.2%。
Margin归因:GAAP Operating Margin提升30 bps至15.9%,Adjusted提升40 bps至16.0%。正面因素:运营效率提升、印度卢比贬值净影响约+100 bps(含对冲)。负面因素:薪酬成本上升、收购摊薄、第三方产品销售影响。此外,GAAP margin受Project Leap费用$84M(-1.5%)和印度公积金负债转回$81M(+1.4%)双重影响,两者均被排除在Adjusted之外。
盈利质量:Net Income下降1.4%至$636M,主要因Project Leap费用及权益法投资亏损$8M。剔除一次性项目后,Adjusted Diluted EPS增长4.6%至$1.37。经营现金流H1为$832M,同比增长$34M,主要因税收支付减少,但被激励薪酬支付增加部分抵消。FCF转化率(FCF/Net Income)约50.6%,处于健康水平。
| 分部 | 营收 | 同比 | 经营利润 | 利润率 | 驱动 |
|---|---|---|---|---|---|
| Health Sciences | $1,572M | +1.4% | $312M | 19.8% | 生命科学需求持续,但第三方产品销售额下降125 bps |
| Financial Services | $1,733M | +12.0% | $277M | 16.0% | 大型交易及AI服务需求强劲,第三方产品销售贡献250 bps |
| Products and Resources | $1,322M | +1.2% | $165M | 12.5% | 零售、消费品等客户 discretionary spend 疲软,制造业等需求增长 |
| Communications, Media and Technology | $854M | +1.5% | $123M | 14.4% | 通信媒体客户疲软,科技客户增长,第三方产品销售贡献350 bps |
注:分部经营利润已按新口径(含公司成本分摊)重述。
| 项目 | 本期 | 上期/变化 |
|---|---|---|
| Cash & ST investments | $1,051M | -$863M vs Dec 2025 |
| Total Debt | $1,560M | +$984M vs Dec 2025 |
| Net Debt | $509M | 由净现金转为净负债 |
| Inventory | — | — |
| RPO | $6,939M | 约35%一年内确认 |
| Operating Cash Flow (H1) | $832M | +$34M |
| Capex (H1) | $175M | +$31M |
| Free Cash Flow (H1) | $657M | +$3M |
| FCF转化率 (H1) | 50.6% | — |
Net Debt/EBITDA(TTM)约0.3倍,杠杆水平较低。Q2借款$1,000M用于收购及回购,剩余信贷额度$850M。
资本配置:
前瞻指引:
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY26 | Project Leap总成本 | $230M-$320M | 报告口径 |
| FY26 | Project Leap节省 | $200M-$300M | 报告口径 |
一次性异常项:
主要风险: